Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York

WEST CHESTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President & Chief Executive Officer, will present at the upcoming Jefferies Healthcare Conference, which is being held at the New York Marriot Marquis from June 7-9, 2023.

Event details:

Date: Thursday, June 8, 2023

Time: 1:00 pm ET

Location: New York Marriot Marquis, 1535 Broadway, New York, NY 10036

Participants may access a live webcast of the event through the following link:

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at . The webcast replay will be available 30 days after the conclusion of live event, and the webcast replay expires on September 15, 2023.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP- 315 (formerly LTX-315 and VP-LTX-315) for dermatologic oncology conditions. For more information, visit .

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

Terry Kohler 

Chief Financial Officer

Kevin Gardner

LifeSci Advisors

Chris Calabrese

LifeSci Advisors